Diphemanil Methylsulfate is a quaternary ammonium anticholinergic, it binds muscarinic acetycholine receptors (mAchR).

1-Methoxy PMS is an electron mediator for NAD(P)H-tetrazolium salt.

N-Type calcium channel inhibitor

Novel potent and selective oxytocin receptor antagonist

Micafungin(FK463) is an echinocandin antifungal drug, Micafungin inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls.

Avibactam sodium(NXL-104) is a non-β-lactam β-lactamase inhibitor antibiotic.

UoS12258 (UoS-12258) is a selective, positive allosteric modulator of the AMPA receptor with pEC50 of 5.6.

LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.

Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist, also inhibits CYP2C9 and 4-hydroxylation with IC50 of 10.5 μM and 8.2 μM respectively.

DS-437 is a potent, selective, dual inhibitor of PRMT5 and PRMT7 with IC50 of 6.0 uM for both, DS-437 is inactive against 29 other human protein-, DNA-, and RNA-methyltransferases.

Apilimod(STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, IL-12 production in cultures of IFN-r/LPS–stimulated human PBMCs is strongly inhibited by STA-5326 with an IC50 of 10 nM.

Apremilast(CC10004) is a novel small molecule inhibitor of PDE4 with an IC50 value of 74 nM.

Bevurogant is a retinoid-related orphan receptor-gamma t (RORγt) antagonist. Bevurogant can be used for the research of chronic inflammatory diseases.

DS18561882 is a potent and isozyme-selective MTHFD2 inhibitor with GI50 of 140 nM, which also shows good oral pharmacokinetic profile.

Ziftomenib is a menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151).

Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue.

N-Formyl-Met-Leu-Phe, also known as fMLF, is a potent neutrophil chemoattractant and the reference agonist for the G protein-coupled N-formylpeptide receptor (FPR).

Exatecan mesylate is a semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity.

Fexinidazole is a new Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

MOTS-c, a mitochondria-derived peptide (MDP), exerts antinociceptive and anti-inflammatory effects through activating AMPK pathway and inhibiting MAP kinases-c-fos signaling pathway.

Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM.

Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

AMI-1 is a PRMT and HIV-1 RT polymerase inhibitor.

Alofanib ((RPT-835) is a potent, selective, allosteric FGFR2 inhibitor that significantly inhibits bFGF-induced proliferation of HUVEC cells with IC50 of 11 nM

Argatroban monohydrate is a direct, selective thrombin inhibitor.

ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.

KN-62 is a sective, cell-permeable inhibitor of CaM kinase II (IC50 = 0.9 μM).

Cintirorgon (LYC-55716) is novel oral RAR-related orphan receptor γ (RORγ) agonist.

BI-78D3 is a competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K.